Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Acquired haemophilia: dynamic whole blood coagulation utilized to guide haemostatic therapy.

Haemophilia : the official journal of the World Federation of Hemophilia - 1 Mar 2006

Johansen R F, Sørensen B, Ingerslev J

Abstract excerpt

Acquired haemophilia is a rare bleeding disorder caused by autoimmune antibodies interacting with factor VIII (FVIII) or factor IX. Anticipating a high degree of heterogeneity amongst cases, we recently initiated systematic recording of whole blood (WB) coagulation dynamic profiles using our recently developed thrombelastographic method employing very small amounts of tissue factor for activation. Six newly...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Blood Coagulation
Share to Coagulants
Share to Drug Monitoring

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Factor VIIa

Share to Factor VIII

Share to Hemophilia A

Share to Hemostasis

Share to Recombinant Proteins

Source

Identifiers

PMID: 16476097
DOI: 10.1111/j.1365-2516.2006.01166.x

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Acquired haemophilia: dynamic whole blood coagulation utilized to guide haemostatic therapy.PMID 16476097Read ↗

Whole blood clot formation phenotypes in hemophilia A and rare coagulation disorders. Patterns of response to recombinant factor VIIa.Semantic proximity Read ↗

Prophylactic Therapy with Emicizumab in Patients with Hemophilia A: Benefits and ChallengesSemantic proximity Read ↗

In vitro evaluation of global coagulation potential in the copresence of emicizumab and warfarin in whole blood using rotational thromboelastometrySemantic proximity Read ↗

Overall hemostasis potential and aPTT-clot waveform analysis as powerful laboratory diagnostic tools for identification of hemophilia A patients with unexpected bleeding phenotype.Semantic proximity Read ↗

Refractory obstetric hemorrhage as the initial presentation of acquired hemophilia: diagnostic limitations of viscoelastic testing in the presence of factor VIII inhibitors. A case report and literature reviewSemantic proximity Read ↗

Clinical heterogeneity of acquired hemophilia A: a description of 4 cases.Semantic proximity Read ↗

Thrombin activatable fibrinolysis inhibitor activation and bleeding in haemophilia A.Semantic proximity Read ↗

Bleeding phenotype of patients with moderate haemophilia A and B assessed by thromboelastometry and thrombin generation.Semantic proximity Read ↗

On‐demand treatment of bleeds in haemophilia patients with inhibitors: strategies for securing and maintaining predictable efficacy with recombinant activated factor VIISemantic proximity Read ↗

Clot lysis phenotype and response to recombinant factor VIIa in plasma of haemophilia A inhibitor patients.Semantic proximity Read ↗

Recent advances in developing specific therapies for haemophiliaSemantic proximity Read ↗

The phenotypic heterogeneity of severe hemophilia.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.